Lisata Therapeutics (NASDAQ:LSTA) Trading Up 4.3% – Time to Buy?

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s share price was up 4.3% during trading on Wednesday . The stock traded as high as $4.04 and last traded at $3.61. Approximately 866,986 shares changed hands during mid-day trading, an increase of 391% from the average daily volume of 176,541 shares. The stock had previously closed at $3.46.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Zacks Research raised Lisata Therapeutics to a “hold” rating in a report on Monday, May 18th. HC Wainwright downgraded Lisata Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Lisata Therapeutics has a consensus rating of “Reduce” and a consensus price target of $15.00.

Lisata Therapeutics Stock Performance

The stock has a market cap of $32.42 million, a PE ratio of -1.91 and a beta of 0.81. The business has a 50-day moving average of $3.62 and a 200 day moving average of $3.50.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.50) EPS for the quarter. Equities analysts expect that Lisata Therapeutics, Inc. will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

A number of institutional investors have recently made changes to their positions in LSTA. Renaissance Technologies LLC raised its position in shares of Lisata Therapeutics by 6.5% during the 1st quarter. Renaissance Technologies LLC now owns 131,715 shares of the company’s stock valued at $660,000 after acquiring an additional 8,000 shares in the last quarter. Deltec Asset Management LLC acquired a new stake in shares of Lisata Therapeutics during the 1st quarter valued at approximately $451,000. Rangeley Capital LLC bought a new position in Lisata Therapeutics during the 1st quarter worth $376,000. Ground Swell Capital LLC increased its position in Lisata Therapeutics by 64.0% in the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after buying an additional 15,213 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new stake in Lisata Therapeutics in the third quarter worth $37,000. 8.94% of the stock is owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.